Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Replimune Group Inc (REPL)  
$9.83 0.05 (0.51%) as of 4:30 Mon 6/16


Download
   
Exchange: N/A
Security Type: Common
Shares Out: 86,076,000
Market Cap: 846.13(M)
Last Volume: 0 Avg Vol: 0
52 Week Range: $6.92 - $14.93
Level I Sector: N/A
Level II Sector: N/A
Level III Sector: N/A

Member Indexes:
   

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  861
Guru Rank Value     : 2.2
Guru Occurances    : 2

 

            6 Months   1 Year   2 Year  
 
Company Profile   Replimune Group is a clinical-stage biotechnology company focused on applying its capabilities in the field of oncolytic immunotherapy to transform the lives of cancer patients through its tumor-directed oncolytic immunotherapies. Co.'s RPx product candidates in its development pipeline include: RP1, which is a selectively replicating version of herpes simplex virus 1 that expresses GALV-GP R(-) and human GM-CSF; RP2, which expresses an anti-CTLA-4 antibody-like protein intended to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3, which expresses immune-activating proteins that stimulate T cells, in addition to anti-CTLA-4 and GALV-GP R(-).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 74,907 84,907 106,298 278,489
Total Sell Value $603,654 $727,854 $953,086 $2,788,980
Total People Sold 6 6 6 9
Total Sell Transactions 6 7 10 25
End Date 2025-03-16 2024-12-13 2024-06-14 2023-06-15

   
Records found: 197
  Page 1 of 8  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Sarchi Christopher Chief Commercial Officer   •       –      –    2025-05-20 4 S $8.05 $30,179 D/D (3,749) 128,296 -6%     
   Astley-Sparke Philip Director   –       •      –    2025-05-20 4 S $8.06 $260,169 D/D (32,279) 1,405,071 -6%     
   Patel Sushil Chief Executive Officer   •       •      –    2025-05-20 4 S $8.06 $202,346 D/D (25,105) 343,576 -6%     
   Xynos Konstantinos Chief Medical Officer   •       –      –    2025-05-20 4 S $8.06 $64,093 D/D (7,952) 146,933 -6%     
   Schwendenman Andrew Chief Accounting Officer   •       –      –    2025-05-20 4 S $8.05 $26,460 D/D (3,287) 68,284 -6%     
   Hill Emily Luisa Chief Financial Officer   •       –      –    2025-05-20 4 S $8.05 $20,407 D/D (2,535) 143,522 -6%     
   Hill Emily Luisa Chief Financial Officer   •       –      –    2025-04-01 4 A $0.00 $0 D/D 45,000 146,057     -
   Sarchi Christopher Chief Commercial Officer   •       –      –    2025-04-01 4 A $0.00 $0 D/D 45,000 132,045     -
   Xynos Konstantinos Chief Medical Officer   •       –      –    2025-04-01 4 A $0.00 $0 D/D 45,000 154,885     -
   Schwendenman Andrew Chief Accounting Officer   •       –      –    2025-04-01 4 A $0.00 $0 D/D 33,333 71,571     -
   Patel Sushil Chief Executive Officer   •       •      –    2025-04-01 4 A $0.00 $0 D/D 166,667 368,681     -
   Baker Julian   –       •       •   2025-03-05 3 IO $0.00 $0 I/I 0 11,045,336 -20%     
   Patel Sushil Chief Executive Officer   •       •      –    2024-12-16 4 AS $12.42 $124,200 D/D (10,000) 202,014 -25%     
   Xynos Konstantinos Chief Medical Officer   •       –      –    2024-11-18 4 S $10.78 $78,112 D/D (7,246) 109,885 22%     
   Sarchi Christopher Chief Commercial Officer   •       –      –    2024-11-18 4 S $10.78 $56,131 D/D (5,207) 87,045 22%     
   Astley-Sparke Philip Executive Chairman   •       •      –    2024-08-30 4 GD $0.00 $0 D/D 50,000 1,437,350     -
   Hill Emily Luisa Chief Financial Officer   •       –      –    2024-08-16 4 S $10.18 $90,989 D/D (8,938) 101,057 -24%     
   Xynos Konstantinos Chief Medical Officer   •       –      –    2024-06-07 4 AS $7.50 $119,108 D/D (15,881) 117,131 43%     
   Xynos Konstantinos Chief Medical Officer   •       –      –    2024-05-16 4 S $6.47 $41,194 D/D (6,367) 133,012 -66%     
   Coffin Robert Director   –       •      –    2024-05-16 4 S $6.47 $74,172 D/D (11,464) 1,821,872 -66%     
   Schwendenman Andrew Chief Accounting Officer   •       –      –    2024-05-16 4 S $6.47 $14,868 D/D (2,298) 38,238 -66%     
   Love Colin Chief Operating Officer   •       –      –    2024-05-16 4 S $6.47 $113,969 D/D (17,615) 777,345 -66%     
   Sarchi Christopher Chief Commercial Officer   •       –      –    2024-05-16 4 S $6.47 $14,350 D/D (2,218) 92,252 -66%     
   Astley-Sparke Philip Executive Chairman   •       •      –    2024-05-16 4 S $6.47 $245,394 D/D (37,928) 1,487,350 -66%     
   Patel Sushil Chief Executive Officer   •       •      –    2024-05-16 4 S $6.47 $130,655 D/D (20,194) 212,014 -66%     
  197 Records found
  1  2  3  4  5  6  7  8   
  Page 1 of 8
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2025 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us